Bio-Path Holdings - רווח למניה בשנים עשר החודשים האחרונים BPTH

Bio-Path Holdings (BPTH) utilizes a platform gene neutralization method that reduces R&D costs, as illustrated by the rolling year net income per share trend. The value -8.27 describes the current status of this metric. High pricing power in hematology is coupled with a lack of financial scaling, as the company remains in the clinical testing stage with fixed costs.

For Bio-Path Holdings (BPTH), the 12-month net income per share chart reflects the actual efficiency of capital utilization. The eps_ttm_co metric measures the final financial result distributed across the total share issuance for the year. The current value of -8.27 demonstrates the development stage of oncology drugs. The absence of market pricing power makes this indicator a measure of business viability. It is critical for investors to compare this figure with the potential for future commercialization of unique technologies.